

# SPARK

BERLIN

in partnership with



THE JOINT TECHNOLOGY TRANSFER OF  
THE BERLIN INSTITUTE OF HEALTH AND  
CHARITÉ – UNIVERSITÄTSMEDIZIN BERLIN

# LECTURE SERIES

Spark is an initiative created at Stanford University, to overcome challenges associated with translation of academic discoveries. And now in Berlin!



[www.spark-berlin.org](http://www.spark-berlin.org)



MARCH 20TH  
NEXT SPARK

EDUCATIONAL FORUM

# CLINICAL TRIAL DESIGN

5:00 – 7:00 PM  
VIRCHOWWEG 6  
CCO 04-005

PROF. RICARDO HERMOSILLA, **ROCHE**

PROF. ANTONIO PEZZUTTO, **MDC, CHARITÉ**

DR. MATTHIAS OBENAU, **CHARITÉ**

A crucial piece of every drug development program is the introduction of the drug into humans. Designing clinical trials around a compound involves and requires multiple disciplines and expertise, including clinical and biostatistics in order to be able to run GMP-conform and ethically sound, reliable, studies that can give the relevant data output. Some of the challenges met when designing a clinical trial concerns finding the right indications and implementing the right inclusion and exclusion criteria, as well as proper documentation to ensure regulatory compliance.

In this forum, we will highlight the general, and dive into some of the more specific requirements for setting up clinical trials. We are delighted to have Ricardo Hermosilla, Translational medicine leader at Roche, as the first speaker of the evening. He will give us an overview of the subject, and tell us about clinical trials in rare disease in particular. In the second lecture, Antonio Pezzutto and Matthias Obenaus will share their experiences with us from their current work of designing a clinical trial for a MAGE-A1-specific cellular product in leukemia. Their talk will highlight the specifics of designing a clinical trial for an Advanced Therapeutic Medical Product (ATMP).